Nicholson R I, Hutcheson I R, Harper M E, Knowlden J M, Barrow D, McClelland R A, Jones H E, Wakeling A E, Gee J M W
Tenovus Centre for Cancer Research, Welsh School of Pharmacy, Cardiff, Wales.
Ann N Y Acad Sci. 2002 Jun;963:104-15. doi: 10.1111/j.1749-6632.2002.tb04101.x.
An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antihormones are likely to be a composite of the estrogen receptor and growth factor inhibitory activity of these agents. The modulation of growth factor networks during endocrine response is examined, and in vitro and clinical evidence is presented that epidermal growth factor receptor signaling, maintained in either an estrogen receptor-dependent or a receptor-independent manner, is critical to antihormone-resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor Iressa (ZD 1839) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.
越来越多的证据表明，在乳腺癌生长的控制中，生长因子网络与雌激素受体信号高度相互作用。因此，肿瘤对抗激素的反应可能是这些药物的雌激素受体和生长因子抑制活性的综合结果。本文研究了内分泌反应过程中生长因子网络的调节，并提供了体外和临床证据，表明以雌激素受体依赖或非受体依赖方式维持的表皮生长因子受体信号传导，对于抗激素耐药性乳腺癌细胞的生长至关重要。本文强调了表皮生长因子受体选择性酪氨酸激酶抑制剂易瑞沙（ZD 1839）在有效治疗甚至预防内分泌耐药性乳腺癌方面的巨大潜力。
